Table 2.

Demographic details

	Parameter	Criteria	n (%)
1	Gender	Male:Female	56 (84.85):10 (15.15)
2	Periorbital swelling	Absent:Present	29 (43.94):37 (56.06)
3	Periorbital pain	Absent:Present	16 (24.24):50 (75.76)
4	Facial numbness	Absent:Present	24 (36.36):42 (63.64)
5	Extra-ocular movements	Normal:Restricted:Frozen	29 (43.94):20 (30.3):17 (25.76)
6	Vision status	Normal:Reduced:FCCF:PL Negative	26 (39.39):21 (31.82):1 (1.52):18 (27.27)
7	Proptosis	Absent:Present	44 (66.67):22 (33.33)
8	Palatal involvement	Absent:Present	45 (68.18):21 (31.82)
9	Cranial nerve Involvement	Absent:Present	48 (72.73):18 (27.27)
10	Ptosis	Absent:Present	39 (59.09):27 (40.91)
11	H/o diabetes	Absent:Present	15 (22.73):51 (77.27)
12	H/o hypertension	Absent:Present	43 (65.15):23 (34.85)
13	HbA1c	< 6.5:≥ 6.5	10 (15.15) 56 (84.85)
14	Side involved	Unilateral:Bilateral	60 (90.91):6 (9.09)
15	CT severity index	Mild (1-8):Moderate (9-16):Severe (≥ 17)	34 (51.52):28 (42.42):4 (6.06)
16	Final organism	Mucormycosis:Aspergillosis:Both	45 (68.18):9 (13.64):12 (18.18)
17	Clinical outcome	Responder:Non-responder	43 (65.15):23 (34.85)
18	Survival	Survived:Expired	56 (84.85):10 (15.15)
19	Diagnosis of COVID-19 before IFS	After:Before	9 (13.63):57 (86.36)
20	Environment	Rural:Urban	20 (30.3):46 (69.7)
21	TALMI staging	Stage 1:Stage 2:Stage 3:Stage 4	2 (3.03):31 (46.97):7 (10.61):26 (39.39)
22	Steroid given for COVID-19 (n = 57)	Not given:Given	24 (42.1):33 (57.89)

CT: Computed tomography; COVID-19: Coronavirus disease 2019.